Biosynth AG
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Oct 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Multivalent glycoconjugate vaccines (US 10,300,135) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Mar 8, 2027The maintenance fee for Method for detection of beta-D-glucuronidase activity in a sample (US 9,127,303) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 1 fee due Apr 13, 2027The maintenance fee for Applications of Indoloindole and Indoloquinoline dyes (US 9,157,917) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria (US 10,500,263) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,940,909 | Indicator platform In force · From the USPTO record | In force | From the USPTO record | |
| US 9,157,917 | Applications of Indoloindole and Indoloquinoline dyes In force · From the USPTO record | In force | From the USPTO record | |
| US 9,127,303 | Method for detection of beta-D-glucuronidase activity in a sample In force · From the USPTO record | In force | From the USPTO record | |
| US 9,951,306 | Catalase in growth media In force · From the USPTO record | In force | From the USPTO record | |
| US 11,147,872 | Multivalent glycoconjugate vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 11,547,755 | Multivalent glycoconjugate vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 10,300,135 | Multivalent glycoconjugate vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 10,500,263 | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria In force · From the USPTO record | In force | From the USPTO record | |
| US 11,246,919 | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria In force · From the USPTO record | In force | From the USPTO record | |
| US 11,576,959 | Glycoconjugate Vaccines Comprising Basic Units of a Molecular Construct Expressing Built-In Multiple Epitopes for the Formulation of a Broad-Spectrum Vaccine Against Infections Due to Enteropathogenic Bacteria In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 15: 3 lapsed for an unpaid fee · 12 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 1 abandoned